NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- China revises regulations on protection of new plant varieties
- China launches mandatory audits to bolster personal information protection
- Delivering social benefits
- Shenzhou XIX crew returns safely to 'beautiful, blue' Earth
- Ordinary work, extraordinary workers
- AI agent to improve international law services in Shanghai
